Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Date:8/14/2008

ing for making related regulatory filings; our ability to estimate accurately the amount of cash to be used to fund operations over the next 12 months, our ability to obtain future financing and fund the product development of our pipeline; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2007 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

---FINANCIALS ATTACHED---

Pharmacyclics, Inc.

(a development stage enterprise)

Condensed Statements of Operations

(unaudited) (in thousands, except per share data)

Three Months Twelve Months

Ended June 30, Ended June 30,

2008 2007 2008 2007

Grant revenue $-- $107 $-- $126

Operating expenses:

Research and development 3,3
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Pharmacyclics Announces It Received Nasdaq Notification
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised ... secured Otter Capital as a significant new partner. Otter ... GGI’s Agriplier™ technology, building on recent compelling field trial ... first meeting, we have been impressed with Otter Capital’s ... Alan Sobba, President and CEO of GGI. “We look ...
(Date:8/27/2014)... Livermore, California (PRWEB) August 27, 2014 ... (LLNL), through Lawrence Livermore National Security ... million to develop and deliver a state-of-the-art laser ... Beamlines facility (ELI Beamlines), under construction in the ... design performance, the laser system, called the " ...
(Date:8/27/2014)... 2014   MSC , a healthcare performance improvement ... the appointment of Mary Beth Loesch to ... of experience preparing companies for rapid growth and market ... President of Corporate Development and Healthcare. In that role, ... as well as corporate strategy and marketing. Previously, Loesch ...
(Date:8/27/2014)... 2014 The Global and China Trifluoroacetic ... the current state of the Trifluoroacetic Acid industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
Breaking Biology Technology:Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3MSC names Mary Beth Loesch President and CEO 2Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... grounding in science is widely considered to be crucial ... and pharmacists to physician assistants and physical therapists, the ... the fields of healthcare and science. Yet, for the ... Interactive for University of the Sciences ( ...
... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, announced today that it has completed a previously ... Company of approximately $6.5 million. Under the ... of 1,857,143 units to certain institutional investors for a ...
... Calif., June 15, 2011 Synthetic Genomics, Inc. (SGI), ... a variety of global needs including clean renewable energy, ... Mahler will join the company as Chief Financial Officer ... for leading and directing all financial aspect of the ...
Cached Biology Technology:Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 2Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 3Careers in Healthcare and Science? "Not Interested" Say Half of U.S. Teens 4PharmAthene Completes $6.5 Million Registered Direct Offering 2PharmAthene Completes $6.5 Million Registered Direct Offering 3Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer 2
(Date:8/27/2014)... Africa is entering what is described by the Volunteer ... The Eastern Cape provincial government warned residents in ... strong winds and veld fires. A high veld ... and along the coast in the Great Kei and ... regions, and during thunderstorms. The thunderstorms bring lightning ...
(Date:8/27/2014)... beasts. But every creature is a baby once. , ... of 24 very young dinosaurs and one older individual ... a caretaker, according to a new study by University ... Peter Dodson led the work, collaborating with researchers from ... is held. Hedrick is a doctoral student in the ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... December, 2010 Elsevier, the world-leading publisher of scientific, ... that it is participating in the recently launched Google ... eBook titles. Elsevier regards Google eBooks as a valuable ... its scientific and professional ebook content in the United ...
... (i.e., estrogen produced by ovaries and by other tissues) ... (HRT) utilizing estrogen alone (the exogenous estrogen) provides a ... study results presented at the 33rd Annual CTRC-AACR San ... "Our analysis suggests that, contrary to previous thinking, there ...
... without saying that conservatives and liberals don,t see the world ... Nebraska-Lincoln suggests that is exactly, and quite literally, the case. ... and conservatives, reaction to "gaze cues" a person,s ... person,s eye movements, even if it,s irrelevant to their current ...
Cached Biology News:Elsevier offers scientific book content through Google eBooks 2Estrogen alone is effective for reducing breast cancer risk 2Look: What your reaction to someone's eye movements says about your politics 2
...
...
... Solid phase reagent ... purification; Easy & unique ... Compatible with detergents and ... & recover non-envelop viruses ...
Synaptic Vesicle I Sampler Kit 10g each...
Biology Products: